RxDoctor Payments Data

Shalin Shah, MD

Ophthalmology · Decatur, GANPI 1457671307

Payments from drug & device makers

$7,932in general payments, 2019–2025

Across 311 payments — averaging $25.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Glaukos Corporation$1K
  • Sun Pharmaceutical Industries Inc.$870
  • Alcon$552
  • Harrow Eye, LLC$491
  • Johnson & Johnson Surgical Vision, Inc.$397
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$7,913100%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,932 in reported general payments places this provider in the 75th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$398,583
Medicare patients
636
Services billed
3,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate554$291,128
CombiganBrimonidine Tartrate/Timolol272$134,505
LumiganBimatoprost247$132,017
RestasisCyclosporine78$102,800
CequaCyclosporine81$78,461
XiidraLifitegrast33$53,127
RocklatanNetarsudil Mesylat/Latanoprost75$40,022
SimbrinzaBrinzolamide/Brimonidine Tart131$39,597
Latanoprost1,938$26,529
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol118$25,923
Travoprost106$21,025
Cyclosporine34$17,972
Alphagan PBrimonidine Tartrate43$17,938
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,124$17,488
Prednisolone Acetate367$16,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan, Lumigan, Restasis, Alphagan P$1,401$387,260640 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$53$331,150629 claims
Sun Pharmaceutical Industries Inc.Cequa$870$78,46181 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Zirgan$167$66,76364 claims
AlconSimbrinza$552$39,597131 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Loteprednol Etabonate$31$15,63255 claims
Oyster Point Pharma, Inc.Tyrvaya$202$10,97715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →